Drug Approval | August 22, 2022
USFDA grants emergency use authorization for Novavax COVID-19 vaccine
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
Phase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines
QIAstat-Dx Viral Vesicular Panel tests for six pathogens that produce similar symptoms
Elecsys HCV Duo is the first commercially available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status.
The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.
Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells
This investment will facilitate a Cipla entity's strategic participation in the Poe diagnostics and AMR space through the design, development, and manufacturing of microfluidics-based technologies
We see significant potential in working with oncolytic virus companies and Neo antigen-companies
To address the preventive & primary healthcare delivery gaps in India
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
Subscribe To Our Newsletter & Stay Updated
